The therapeutic role of lasers in primary localized cutaneous amyloidosis: a systematic review

Ahramiyanpour, Najmeh; Akbari, Zahra; Sarasyabi, Mohammad Sharifi; Aflatoonian, Mahin; Saki, Nasrin; Shafie’ei, Mohammad

doi:10.1007/s10103-021-03429-4

Cited by 6 publications

(7 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on our literature review, reports on treatment of macular amyloidosis are limited to case reports, and studies of patients treated without a control group 2 . Trials are almost about different types of laser therapy 3 . So, limited randomized clinical trial study is performed on using topical agents for treating macular amyloidosis.…”

Section: Discussionmentioning

confidence: 99%

“…The current concept varies from topical, intralesional, or physical treatment with various efficacy. A variety of treatment modalities including topical corticosteroids, topical dimethyl sulfoxide, topical retinoids, oral cyclophosphamide, oral colchicine, phototherapy, laser therapy, surgical intervention, and transcutaneous nerve stimulation have been used, but no particular treatment is effective for all cases 2–4 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of topical gabapentin in women with primary macular amyloidosis: A side‐by‐side triple‐blinded randomized clinical trial

Abtahi‐Naeini,

Hemati,

Faghihi

et al. 2024

J of Cosmetic Dermatology

View full text Add to dashboard Cite

BackgroundPrimary cutaneous macular amyloidosis (PCMA) is a chronic pruritic cutaneous disease characterized by heterogeneous extracellular deposition of amyloid protein in the skin.AimsThis study aimed to evaluate the efficacy of topical 6% gabapentin cream for the treatment of patients with PCMA.Materials and MethodsIn this triple‐blind clinical trial, a total of 34 patients, who were diagnosed with PCMA, treated using two different strategies of topical gabapentin as the active group and vehicle cream as the control group.ResultsPruritus score reduction in both groups was statistically significant compared with the baseline value (p < 0.001). There was a significant pigmentation score reduction in intervention group compared with control group after 1 month of the study (p < 0.001). The differences of pigmentation score changes between the groups were not significant at month 2 (p = 0.52) and month 3 (p = 0.22).ConclusionsThe results of this study suggest that topical gabapentin cream may be effective as a topical agent in the treatment of pruritus associated with PCMA without any significant adverse effects. It is recommended to perform similar studies with a larger sample size and longer duration in both sexes.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Efficacy of topical gabapentin in women with primary macular amyloidosis: A side‐by‐side triple‐blinded randomized clinical trial

Abtahi‐Naeini,

Hemati,

Faghihi

et al. 2024

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

“…If the lesions persist, whether it is a localized LA, it is possible to substitute or add topical drugs to surgical removal (electrodesiccation, a special technique called 'scraping with the scalpel', and dermabrasion) or laser removal [13][14][15]. If it is diffuse LA, on the other hand, phototherapy (narrow-band UVB and photochemotherapy with PUVA) and/or systemic drug treatment (oral antihistamines, DMSO, acitretin or other retinoids, cyclophosphamide, and cyclosporine) can be used [3,[16][17][18].…”

Section: Introductionmentioning

confidence: 99%

Lichen Amyloidosis in an Atopic Patient Treated with Dupilumab: A New Therapeutic Option

Tirone,

Cazzato,

Ambrogio

et al. 2024

Diseases

View full text Add to dashboard Cite

Lichen amyloidosis (LA) is a type of cutaneous amyloidosis characterized by brownish hyperkeratotic and itchy papules on the lower leg, back, forearm, or thigh. It is associated with itching and atopic dermatitis (AD) according to an etiopathogenetic mechanism that has not yet been fully elucidated. Currently, the available therapies for this condition include oral antihistamines, laser, cyclosporine, topical corticosteroids, and phototherapy, but, in light of the overlap with AD, Dupilumab may also be indicated. We report the case of a female, 52 years old, who had been suffering from AD and LA for about 27 years. She had lesions attributable to both diseases on the trunk and lower limbs associated with severe itching and had proved resistant to cyclosporine therapy. It was decided to opt for Dupilumab with the induction of 2 fl of 300 mg and maintenance with 1 fl every other week. The therapy proved to be effective, returning a total resolution of both diseases one year after the beginning of the treatment. Dupilumab demonstrated efficacy and safety in the LA related to AD and led to clinical and quality of life improvements in this patient. Therefore, Dupilumab should be considered when treating LA. Further studies should be conducted focusing on the efficacy of the drug on LA (whether or not related to AD), changes in the skin lesions after discontinuation, and the safety of long-term application.

show abstract

“…Many publications have shown the efficiency of laser therapy on PLCA [38]. Carbon dioxide laser has demonstrated successful clinical outcomes in the treatment of MA and LA lesions [39,40].…”

Section: Introductionmentioning

confidence: 99%

Primary Localized Cutaneous Amyloidosis in Central Europe: A Retrospective Monocentric Study on Epidemiology and Therapy

Pálla,

Kuroli,

Tóth

et al. 2023

JCM

View full text Add to dashboard Cite

Amyloid deposits can be the cause of many chronic diseases. Primary localized cutaneous amyloidosis (PLCA) is a chronic dermatologic condition with amyloid deposits in the papillary dermis. The most common types of the keratinocyte-derived form of PLCA include macular (MA), lichen (LA), and biphasic (BA) amyloidosis. The estimated prevalence of PLCA in the Asian population is 0.98/10,000, which is higher than in the European population; thus, epidemiologic data on PLCA in the Caucasian population are limited. We performed a retrospective single-center study analyzing epidemiologic characteristics of a Central European PLCA population. Epidemiologic data regarding age, sex, skin phototype (Fitzpatrick scale I–VI), disease duration, comorbidities, history of atopy, and family history of PLCA were collected. Clinical characteristics, localization of PLCA lesions, applied therapies and treatment outcomes were also analyzed. Dermoscopic characteristics were also evaluated. A total of 41 patients diagnosed with PLCA were included, with 22 presenting with macular, 18 with lichen, and 1 with biphasic amyloidosis. The male/female ratio was 16/25, and mean age at diagnosis was 54.6 ± 15.2 years (range 27–87 years). The mean age at the onset of PLCA was 53 ± 16.1 years (range 19–79 years) in MA, 46.7 ± 18.2 years (range 14–73 years) in LA, and 26 years in BA. The interscapular region in MA and the extensor surface of the lower extremities in LA proved to be localization-related areas. In our center, a wide range of therapeutic options was applied, with the most prescribed being topical corticosteroids in all types of PLCA. We presented a retrospective, monocentric study on the epidemiology of PLCA in the Central European region. By examining the medical data of a significant number of PLCA patients, we compared our epidemiologic data with that of the Asian PLCA population. Due to the rarity of the condition, further randomized controlled trials and guidelines are needed to improve therapeutic outcomes.

show abstract

The therapeutic role of lasers in primary localized cutaneous amyloidosis: a systematic review

Cited by 6 publications

References 31 publications

Efficacy of topical gabapentin in women with primary macular amyloidosis: A side‐by‐side triple‐blinded randomized clinical trial

Efficacy of topical gabapentin in women with primary macular amyloidosis: A side‐by‐side triple‐blinded randomized clinical trial

Lichen Amyloidosis in an Atopic Patient Treated with Dupilumab: A New Therapeutic Option

Primary Localized Cutaneous Amyloidosis in Central Europe: A Retrospective Monocentric Study on Epidemiology and Therapy

Contact Info

Product

Resources

About